Department of Anesthesiology and Pain Medicine, University of Washington Medical Center, Seattle, WA, USA.
Int J Obstet Anesth. 2013 Apr;22(2):133-45. doi: 10.1016/j.ijoa.2013.01.008. Epub 2013 Mar 9.
With over four million deliveries annually in the United States alone and a constant increase in cesarean delivery rate, childbirth is likely to have a huge impact on the occurrence of acute and possibly chronic postpartum pain. Recent awareness that chronic pain may occur after childbirth has prompted clinicians and researchers to investigate this topic. Current evidence points towards a relatively low incidence of chronic pain after cesarean delivery, with rates ranging between 1% and 18%. To provide a potential mechanistic explanation for the relatively low occurrence of chronic pain after cesarean delivery compared with that after other types of surgery, it has been proposed that endogenous secretion of oxytocin may confer specific protection. Clinical interventions to reduce the incidence and severity of chronic post-surgical pain have not been consistently effective. Likely explanations are that the drugs that have been investigated were truly ineffective or that the effect was too modest because with a low incidence of chronic pain, studies were likely to be underpowered and failed to demonstrate an effect. In addition, since not all women require preventive therapies, preoperative testing that may identify women vulnerable to pain may be highly beneficial. Further research is needed to identify valid models that predict persistent pain to allow targeted interventions to women most likely to benefit from more tailored anti-hyperalgesic therapies.
仅在美国,每年就有超过 400 万次分娩,而且剖宫产率不断上升,分娩很可能对急性和可能的慢性产后疼痛的发生产生巨大影响。最近人们意识到,分娩后可能会出现慢性疼痛,这促使临床医生和研究人员调查这一课题。目前的证据表明,剖宫产术后慢性疼痛的发生率相对较低,为 1%至 18%。为了提供一个可能的机制解释,即与其他类型的手术后相比,剖宫产术后慢性疼痛的发生率相对较低,有人提出,内源性催产素的分泌可能提供了特定的保护。减少慢性手术后疼痛发生率和严重程度的临床干预措施并不总是有效。可能的解释是,已经研究过的药物确实无效,或者效果太小,因为慢性疼痛的发生率较低,研究可能没有足够的效力,无法证明效果。此外,由于并非所有女性都需要预防性治疗,因此术前检查可能会识别出容易疼痛的女性,这可能非常有益。需要进一步研究来确定有效的模型,以预测持续性疼痛,从而针对最有可能从更有针对性的抗痛觉过敏治疗中受益的女性进行干预。